IP Library Granted Patent US 9,957,276
Granted Patent B2
US 9,957,276 · App. 15/348,770 · Granted May 1, 2018

CDK inhibitors

Inventors: Francis X. Tavares (Durham, NC); Jay C. Strum (Hillsborough, NC)
Assignee: GI Therapeutics, Inc.
C07D487/14A61K31/499C07D487/20C07D498/14C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,957,276
App. No.
15/348,770
Granted
May 1, 2018
Kind
B2
Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Claims (109)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

Z is —(CH 2 ) x — wherein x is 2 or 3;

each X is independently CH or N;

each R 1 is independently aryl, alkyl, or cycloalkyl, wherein two R 1 s on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle;

y is 0, 1, 2, or 3;

R 2 is -(alkylene) m -heterocyclo, -(alkylene) m -heteroaryl, -(alkylene) m -NR 3 R 4 , -(alkylene) m -C(O)—NR 3 R 4 , -(alkylene) m -C(O)—O-alkyl, -(alkylene) m -O—R 5 , -(alkylene) m -S(O) n —R 5 , or -(alkylene) m -S(O) n —NR 3 R 4 any of which may be optionally independently substituted with one or more R x groups as allowed by valence;

m is 0 or 1;

n is 1 or 2;

R 3 and R 4 at each occurrence are independently:

(i) hydrogen or

(ii) alkyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, or heteroarylalkyl, or R 3 and R 4 together with the nitrogen atom to which they are attached may combine to form a heterocyclo ring;

R 5 is:

(i) hydrogen or

(ii) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, arylalkyl, or heteroarylalkyl;

R x at each occurrence is independently, halo, cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkyl; and

R 6 is a lower alkyl or absent.

2. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 having formula:

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein x 2.

13. The compound of claim 1 , wherein y is 0, 1, or 2.

14. The compound of claim 1 , wherein R 2 is -(alkylene) m -heterocyclo, -(alkylene) m -NR 3 R 4 , -(alkylene) m -C(O)—NR 3 R 4 ; -(alkylene) m -C(O)—O-alkyl, or -(alkylene) m -O—R 5 .

15. The compound of claim 1 , wherein R 2 is -(alkylene) m -heterocyclo or -(alkylene) m -heteroaryl.

16. The compound of claim 1 , wherein R 2 is -(alkylene) m -heterocyclo.

17. The compound of claim 16 , wherein m is 0.

18. The compound of claim 1 , wherein R 2 is substituted with one R x group.

19. The compound of claim 1 , wherein R x is selected from alkyl, cycloalkyl, and heterocyclo.

20. The compound of claim 1 , wherein R 6 is absent.

21. The compound of claim 1 , wherein both of X are N.

22. The compound of claim 1 , wherein one X is N and the other is CH.

23. The compound of claim 22 , wherein x is 2.

24. The compound of claim 23 , wherein y is 0, 1, or 2.

25. The compound of claim 24 , wherein R 2 is -(alkylene) m -heterocyclo.

26. The compound of claim 25 , wherein m is 0.

27. The compound of claim 26 , wherein R 2 is substituted with one R x group.

28. The compound of claim 27 , wherein R x is selected from alkyl, cycloalkyl, and heterocyclo.

29. The compound of claim 28 , wherein R 6 is absent.

30. The compound of claim 29 , wherein y is 2.

31. The compound of claim 30 , wherein two R 1 s on the same ring atom together with the ring atom to which they are attached form a 3-8-membered cycle.

32. The compound of claim 31 , wherein the 3-8-membered cycle is a 6-membered cycle.

33. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

Z is —(CH 2 ) x — wherein x is 2 or 3;

each X is independently CH or N;

each R 1 is independently aryl, alkyl, or cycloalkyl, wherein two R 1 s on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle;

y is 0, 1, 2, or 3;

R 6 is a lower alkyl or absent;

R 2 is

R 2 * is a bond, alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - or -(alkylene) m -NH-(alkylene) m -;

P is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group;

each R x1 is independently —(C(O))—O-alkyl, -(alkylene) m -cycloalkyl, —N(R N )-cycloalkyl, —C(O)-cycloalkyl, -(alkylene) m -heterocyclyl, —N(R N )-heterocyclyl, —C(O)-heterocyclyl, or —S(O) 2 -(alkylene) m ;

R N is H, C 1 to C 4 alkyl or C 1 to C 6 heteroalkyl;

m is 0 or 1; and

t is 0, 1 or 2.

34. The compound of claim 33 , wherein x is 2.

35. The compound of claim 33 , wherein y is 0, 1, or 2.

36. The compound of claim 33 , wherein R 6 is absent.

37. The compound of claim 33 , wherein one X is N and the other is CH.

38. The compound of claim 37 , wherein x is 2.

39. The compound of claim 38 , wherein y is 0, 1, or 2.

40. The compound of claim 39 , wherein R 6 is absent.

41. The compound of claim 40 , wherein y is 2.

42. The compound of claim 41 , wherein two R 1 s on the same ring atom together with the ring atom to which they are attached form a 3-8-membered cycle.

43. The compound of claim 42 , wherein the 3-8-membered cycle is a 6-membered cycle.

44. The compound of claim 43 , wherein R 2 is

45. The compound of claim 43 , wherein R 2 is

46. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

Z is —(CH 2 ) x — wherein x is 2 or 3;

each X is independently CH or N;

each R 1 is independently aryl, alkyl, or cycloalkyl, wherein two R 1 s on adjacent ring atoms or on the same ring atom together with the ring atom(s) to which they are attached optionally form a 3-8-membered cycle;

y is 0, 1, 2, or 3;

R 6 is a lower alkyl or absent;

R 2 is

R 2 * is a bond, alkylene, -(alkylene) m -O-(alkylene) m -, -(alkylene) m -C(O)-(alkylene) m -, -(alkylene) m -S(O) 2 -(alkylene) m - or -(alkylene) m -NH-(alkylene) m -;

P is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group;

P1 is a 4- to 6-membered monocyclic saturated heterocyclyl group;

each R x2 is independently hydrogen or alkyl;

m is 0 or 1; and

s is 0, 1 or 2.

47. The compound of claim 46 , wherein x is 2.

48. The compound of claim 46 , wherein y is 0, 1, or 2.

49. The compound of claim 46 , wherein R 6 is absent.

50. The compound of claim 46 , wherein one X is N and the other is CH.

51. The compound of claim 50 , wherein x is 2.

52. The compound of claim 51 , wherein y is 0, 1, or 2.

53. The compound of claim 52 , wherein R 6 is absent.

54. The compound of claim 53 , wherein y is 2.

55. The compound of claim 54 , wherein two R 1 s on the same ring atom together with the ring atom to which they are attached form a 3-8-membered cycle.

56. The compound of claim 55 , wherein the 3-8-membered cycle is a 6-membered cycle.

57. The compound of claim 56 , wherein R 2 is

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 071018/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2025
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 071018/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: G1 THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 069371/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 069371/0832 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 19, 2024
From: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
To: G1 THERAPEUTICS, INC.
Reel/Frame 068996/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055746/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: STRUM, JAY C.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055725/0743 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 29, 2020
From: G1 THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Reel/Frame 052795/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: TAVARES, FRANCIS X.; STRUM, JAY C.
To: G1 THERAPEUTICS, INC.
Reel/Frame 040281/0448 →
Continuity (7)
Continuation 14712582 · May 14, 2015
Continuation 14452296 · Aug 5, 2014
Continuation 14162637 · Jan 23, 2014
Continuation 13869594 · Apr 24, 2013
Continuation PCTUS2011057749 · Oct 25, 2011
Provisional Application 61406498 · Oct 25, 2010
Related Publication 20170057971A1 · Mar 2, 2017